On January 13, the “Launching Ceremony for Beijing R&D Platform of Antibody Medicine” was held in the PLA General Hospital. Wang Anshun who is the Deputy Party Secretary of Beijing, Dai Wei who is the Deputy Secretary General of Beijing Municipal Government, Yan Aoshuang who is the Director of Beijing Municipal Committee of Science & Technology, leaders from Beijing Development and Reform Commission, Beijing Municipal Bureau of Finance and Beijing Economic & Information Commission, Li Shuzhang who is the President of PLA General Hospital, Wen Degong who is the Political Commissar of PLA General Hospital and Xu Jingren who is the Chairman of YRPG presented at the launching ceremony and together unveiled the plaque for the “Beijing R&D Platform of Antibody Medicine”. Beijing Municipal Committee of Science & Technology, PLA General Hospital and YRPG jointly signed the “Strategic Partnership Agreement for the Construction of the Beijing R&D Platform of Antibody Medicine”.
The construction of the R & D platform includes two parts: 1. the construction of the R & D key laboratory. 2. The construction of the platform of pilot test. Under the positive assistance of Beijing Municipal Committee of Science & Technology, YRPG and PLA General Hospital rapidly organized the antibody pilot test and reached a cooperation intention on industrialization. The pilot test of antibody medicine and the production will be supervised by Beijing Haiyan Pharmaceuticals Co., Ltd. of YRPG. The construction of the platform of pilot test will focus on addressing the bottlenecks before the large-scale industrialization of the research achievements and it will mobilize a lot of resources in the fields of enterprises and society. Finally, the industrial chain of “pilot test-production” of antibody medicine of Beijing will be formed.
In the recent 10 years, antibody medicine has become one of the most active fields in the development of biological medicine, which are of significant social and economic benefit. It has become a worldwide focus. The launching of the platform has important strategic significance in enhancing the R & D level of antibody medicine in Beijing and in realizing the industrialization of a series of antibody medicine. Meanwhile, the leapfrog development of biomedicine industry in Beijing moves forwards a further step. After the Beijing R&D Platform of Antibody Medicine is launched, a series of antibody medicine will be successfully developed within 5 years. That will promote the industrial scale of antibody medicine in Beijing to reach the scale of RMB 5 billion to 10 billion. Also, it will make Beijing become the center of R & D of antibody medicine and industrialization within a short period of time in China.
As China’s largest health care hospital throughout the army, PLA General Hospital has the largest medical research and clinical base with the most mature operation. It has also created extremely favorable conditions for the construction of the R&D platform of antibody medicine. Professor Guo Yajun from PLA General Hospital introduced that “after the establishment of the 'Beijing R&D Platform of Antibody Medicine', the specific antibody can be screened out within a short period of time and a large amount of emergency medicine/vaccine can be produced rapidly. It will play an important role in the control and prevention of the epidemic diseases in Beijing or even in China. That means China will be the second country to produce antibody following the US."
The launching of Beijing R&D Platform of Antibody Medicine is like a seed for the research and development of biological medicine. Based on the construction of the platform of antibody medicine, the R&D of antibody medicine will be effectively promoted. The industrialization of the achievements in the field of antibody technology in China will be improved. The army and people can be better merged together. It is a beneficial attempt in the implementation of technological innovation and the system and mechanism of innovation technology under the new situation.